(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 30.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Regenxbio's revenue in 2025 is $161,318,000.On average, 14 Wall Street analysts forecast RGNX's revenue for 2025 to be $12,571,230,946, with the lowest RGNX revenue forecast at $7,510,947,270, and the highest RGNX revenue forecast at $22,165,318,205. On average, 14 Wall Street analysts forecast RGNX's revenue for 2026 to be $12,906,355,776, with the lowest RGNX revenue forecast at $6,936,881,475, and the highest RGNX revenue forecast at $17,695,299,711.
In 2027, RGNX is forecast to generate $19,529,880,348 in revenue, with the lowest revenue forecast at $10,840,933,867 and the highest revenue forecast at $28,156,054,202.